Computational Biology in Drug Discovery
In person only
Drug discovery remains a very long and costly process with reducing attrition a major objective. We have shown previously that using human genetics evidence may increase the chance of success in the clinic for drug targets. In addition, genomics technologies that can measure omics layers or perturb the genome at scale can also be used to identify and validate new drug targets and investigate biology at a systems level. In this talk, using examples, I will describe how genetics and genomics data with computational biology analyses are currently being used in drug discovery and the importance of biological context.
Date: 26 February 2024, 12:00 (Monday, 7th week, Hilary 2024)
Venue: Kennedy Institute of Rheumatology, Headington OX3 7FY
Venue Details: Bernard Sunley Lecture Theatre
Speaker: Dr Philippe Sanseau (GlaxoSmithKline (GSK))
Organising department: Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS)
Organiser: Doris Chan (Kennedy Institute of Rheumatology)
Organiser contact email address: doris.chan@kennedy.ox.ac.uk
Host: Prof Mark Coles (Kennedy Institute of Rheumatology )
Part of: Kennedy Institute Seminars
Booking required?: Not required
Audience: Members of the University only
Editor: Doris Chan